Long-term protection from syngeneic acute lymphoblastic leukemia by CpG ODN-mediated stimulation of innate and adaptive immune responses

Blood

Volumn 114, Issue 12, 2009, Pages 2459-2466

  Seif, Alix E ^a   Barrett, David M ^a   Milone, Michael ^b   Brown, Valerie I ^a,c   Grupp, Stephan A ^a,c   Reid, Gregor S D ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; CPG OLIGONUCLEOTIDE; CPG-OLIGONUCLEOTIDE; OLIGODEOXYRIBONUCLEOTIDE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER REGRESSION; CONTROLLED STUDY; FEMALE; IMMUNE RESPONSE; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; MALE; MINIMAL RESIDUAL DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; TUMOR VOLUME; XENOGRAFT; ADOPTIVE IMMUNOTHERAPY; ANIMAL; BAGG ALBINO MOUSE; CYTOTOXICITY; DRUG EFFECT; GENETICS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MOUSE MUTANT; NONOBESE DIABETIC MOUSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; TRANSGENIC MOUSE;

ANIMALS; CYTOTOXICITY, IMMUNOLOGIC; IMMUNITY, INNATE; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED NOD; MICE, SCID; MICE, TRANSGENIC; OLIGODEOXYRIBONUCLEOTIDES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES; TH1 CELLS;

EID: 70350506568     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-02-203984     Document Type: Article

References (42)

1. Smith M, Ries L, Gurney J, Ross J. Leukemia. In: Ries L, Smith M, Gurney J, et al, eds. Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975- 1995 [National Institutes of Health Publication No. 99-4649]. Bethesda, MD: National Cancer Institute, SEER Program; 1999:17-34.
2. Schultz KR, Pullen DJ, Sather HN, et al. Riskand response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood. 2007;109(3): 926-935.
3. Ries L, Percy C, Bunin G. Introduction. In: Ries L, Smith M, Gurney J, et al, eds. Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975-1995 [National Institutes of Health Publication No. 99-4649]. Bethesda, MD: National Cancer Institute, SEER Program; 1999:1-16.
4. Roy A, Cargill A, Love S, et al. Outcome after first relapse in childhood acute lymphoblastic leukaemia: lessons from the United Kingdom R2 trial. Br J Haematol. 2005;130(1):67-75. (Pubitemid 40979134)
5. Horner M, Ries L. Leukemia. In: Ries L, Young J, Keel G, Eisner M, Lin Y, Horner M, eds. SEER Survival Monograph: Cancer Survival Among Adults: US SEER Program, 1988-2001, Patient and Tumor Characteristics [National Institutes of Health Publication No. 07-6215]. Bethesda, MD: National Cancer Institute, SEER Program; 2007: 243-250.
6. Barrett AJ, Ringden O, Zhang MJ, et al. Effect of nucleated marrow cell dose on relapse and survival in identical twin bone marrow transplants for leukemia. Blood. 2000;95(11):3323-3327. (Pubitemid 30428459)
7. Bunin N, Carston M, Wall D, et al. Unrelated marrow transplantation for children with acute lymphoblastic leukemia in second remission. Blood. 2002;99(9):3151-3157. (Pubitemid 34525292)
8. Ringden O, Labopin M, Gorin NC, et al. Is there a graft-versus-leukaemia effect in the absence of graft-versus-host disease in patients undergoing bone marrow transplantation for acute leukaemia? Br J Haematol. 2000;111(4):1130- 1137. (Pubitemid 32104929)
9. Weisdorf D, Bishop M, Dharan B, et al. Autologous versus allogeneic unrelated donor transplantation for acute lymphoblastic leukemia: comparative toxicity and outcomes. Biol Blood Marrow Transplant. 2002;8(4):213-220. (Pubitemid 34520536)
10. Locatelli F, Zecca M, Rondelli R, et al. Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial. Blood. 2000;95(5):1572-1579. (Pubitemid 30120815)
11. Kebelmann-Betzing C, Körner G, Badiali L, et al. Characterization of cytokine, growth factor receptor, costimulatory and adhesion molecule expression patterns of bone marrow blasts in relapsed childhood B cell precursor ALL. Cytokine. 2001; 13(1):39-50. (Pubitemid 32579221)
12. Cardoso AA, Schultze JL, Boussiotis VA, et al. Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen. Blood. 1996; 88(1):41-48.
13. Maecker B, Mougiakakos D, Zimmermann M, et al. Dendritic cell deficiencies in pediatric acute lymphoblastic leukemia patients. Leukemia. 2006;20(4):645-649.
14. Romanski A, Bug G, Becker S, et al. Mechanisms of resistance to natural killer cell-mediated cytotoxicity in acute lymphoblastic leukemia. Exp Hematol. 2005;33(3):344-352. (Pubitemid 40261316)
15. Grüllich C, Friske V, Finke J. Ex vivo detection of primary leukemia cells resistant to granule cytotoxin-induced cell death: a rapid isolation method to study granzyme-B-mediated cell death. Ann Hematol. 2008;87(9):701-708.
16. Fujii H, Trudeau JD, Teachey DT, et al. In vivo control of acute lymphoblastic leukemia by immunostimulatory CpG oligonucleotides. Blood. 2007; 109(5):2008-2013. (Pubitemid 46348200)
17. Reid GSD, She K, Terrett L, Food MR, Trudeau JD, Schultz KR. CpG stimulation of precursor B-lineage acute lymphoblastic leukemia induces a distinct change in costimulatory molecule expression and shifts allogeneic T cells toward a Th1 response. Blood. 2005;105(9):3641-3647. (Pubitemid 40628211)
18. Wasserman R, Zeng XX, Hardy RR. The evolution of B precursor leukemia in the E-mu-ret mouse. Blood. 1998;92(1):273-282. (Pubitemid 28303203)
19. Zeng XX, Zhang H, Hardy RR, Wasserman R. The fetal origin of B-precursor leukemia in the E-mu-ret mouse. Blood. 1998;92(10):3529-3536. (Pubitemid 28525176)
20. Parry RV, Rumbley CA, Vandenberghe LH, June CH, Riley JL. CD28 and inducible costimulatory protein Src homology 2 binding domains show distinct regulation of phosphatidylinositol 3-kinase, Bcl-xL, and IL-2 expression in primary human CD4 T lymphocytes. J Immunol. 2003; 171(1):166-174.
21. Traunecker A, Oliveri F, Karjalainen K. Myeloma based expression system for production of large mammalian proteins. Trends Biotechnol. 1991; 9(1):109-113.
22. Brown VI, Fang J, Alcorn K, et al. Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7- mediated signaling. Proc Natl Acad Sci U S A. 2003;100(25):15113-15118. (Pubitemid 37518025)
23. Fischer K, Mackensen A. The flow cytometric PKH-26 assay for the determination of T-cell mediated cytotoxic activity. Methods. 2003;31(2): 135-142. (Pubitemid 37075898)
24. Beamer CA, Holian A. Silica suppresses Toll-like receptor ligand-induced dendritic cell activation. FASEB J. 2008;22(6):2053-2063. (Pubitemid 351811481)
25. Chang JS, Chang KLB, Hwang DF, Kong ZL. In vitro cytotoxicitiy of silica nanoparticles at high concentrations strongly depends on the metabolic activity type of the cell line. Environ Sci Technol. 2007;41(6):2064-2068.
26. Krieg AM. Development of TLR9 agonists for cancer therapy. J Clin Invest. 2007;117(5):1184-1194. (Pubitemid 46718403)
27. Chiron D, Bekeredjian-Ding I, Pellat-Deceunynck C, Bataille R, Jego G. Toll-like receptors: lessons to learn from normal and malignant human B cells. Blood. 2008;112(6):2205-2213.
28. Longo PG, Laurenti L, Gobessi S, et al. The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease. Leukemia. 2006;21(1):110-120. (Pubitemid 44921842)
29. Todisco E, Gaipa G, Biagi E, et al. CD40 ligand-stimulated B cell precursor leukemic cells elicit interferon-gamma production by autologous bone marrow T cells in childhood acute lymphoblastic leukemia. Leukemia. 2002;16(10):2046. (Pubitemid 35203447)
30. Hegazy AN, Klein C. Ex vivo priming of CD4 T cells converts immunological tolerance into effective antitumor immunity in a murine model of acute lymphoblastic leukemia. Leukemia. 2008; 22(11):2070-2079.
31. Rousseau RF, Biagi E, Dutour A, et al. Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation. Blood. 2006; 107(4):1332-1341. (Pubitemid 43242366)
32. Labbe A, Nelles M, Walia J, et al. IL-12 immunotherapy of murine leukemia: comparison of systemic versus gene modified cell therapy. J Cell Mol Med. 2008 Jun 28 Postprint; 10.1111/j.1582- 4934.2008.00412.X.
33. Portielje JEA, Lamers CHJ, Kruit WHJ, et al. Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-γ, tumor necrosis factor-α, IL-6, and IL-8 responses. Clin Cancer Res. 2003;9(1):76-83.
34. Berner V, Liu H, Zhou Q, et al. IFN-[gamma] mediates CD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy. Nat Med. 2007;13(3):354-360. (Pubitemid 46376686)
35. Buhtoiarov IN, Sondel PM, Eickhoff JC, Rakhmilevich AL. Macrophages are essential for antitumour effects against weakly immunogenic murine tumours induced by class B CpG-oligodeoxynucleotides. Immunology. 2007; 120(3):412-423.
36. Whitmore MM, DeVeer MJ, Edling A, et al. Synergistic activation of innate immunity by double-stranded RNA and CpG DNA promotes enhanced antitumor activity. Cancer Res. 2004;64(16): 5850-5860. (Pubitemid 39095586)
37. Nakajima C, Uekusa Y, Iwasaki M, et al. A role of interferon-γ (IFN-γ) in tumor immunity: T cells with the capacity to reject tumor cells are generated but fail to migrate to tumor sites in IFN-γ- deficient mice. Cancer Res. 2001;61(8):3399-3405. (Pubitemid 32695032)
38. Cloppenborg T, Stanulla M, Zimmermann M, Schrappe M, Welte K, Klein C. Immunosurveillance of childhood ALL: polymorphic interferon-γ alleles are associated with age at diagnosis and clinical risk groups. Leukemia. 2004;19(1):44-48. (Pubitemid 40090075)
39. Liu C, Lou Y, Lizée G, et al. Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J Clin Invest. 2008;118(3): 1165-1175.
40. Houot R, Levy R. T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. Blood. 2009;113(15):3546-3552.
41. Borowitz MJ, Pullen DJ, Shuster JJ, et al. Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children's Oncology Group study. Leukemia. 2003;17(8):1566-1572.
42. Haining W, Cardoso A, Keczkemethy H, et al. Failure to define window of time for autologous tumor vaccination in patients with newly diagnosed or relapsed acute lymphoblastic leukemia. Exp Hematol. 2005;33(3):286-294. (Pubitemid 40261310)